110 related articles for article (PubMed ID: 23813439)
21. Cbfbeta interacts with Runx2 and has a critical role in bone development.
Kundu M; Javed A; Jeon JP; Horner A; Shum L; Eckhaus M; Muenke M; Lian JB; Yang Y; Nuckolls GH; Stein GS; Liu PP
Nat Genet; 2002 Dec; 32(4):639-44. PubMed ID: 12434156
[TBL] [Abstract][Full Text] [Related]
22. Runx1-Cbfβ facilitates early B lymphocyte development by regulating expression of Ebf1.
Seo W; Ikawa T; Kawamoto H; Taniuchi I
J Exp Med; 2012 Jul; 209(7):1255-62. PubMed ID: 22665574
[TBL] [Abstract][Full Text] [Related]
23. Cbf beta regulates Runx2 function isoform-dependently in postnatal bone development.
Kanatani N; Fujita T; Fukuyama R; Liu W; Yoshida CA; Moriishi T; Yamana K; Miyazaki T; Toyosawa S; Komori T
Dev Biol; 2006 Aug; 296(1):48-61. PubMed ID: 16797526
[TBL] [Abstract][Full Text] [Related]
24. Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
Heilman SA; Kuo YH; Goudswaard CS; Valk PJ; Castilla LH
Cancer Res; 2006 Dec; 66(23):11214-8. PubMed ID: 17145866
[TBL] [Abstract][Full Text] [Related]
25. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
Cammenga J; Niebuhr B; Horn S; Bergholz U; Putz G; Buchholz F; Löhler J; Stocking C
Cancer Res; 2007 Jan; 67(2):537-45. PubMed ID: 17234761
[TBL] [Abstract][Full Text] [Related]
26. Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.
Kilbey A; Terry A; Wotton S; Borland G; Zhang Q; Mackay N; McDonald A; Bell M; Wakelam MJ; Cameron ER; Neil JC
J Cell Biochem; 2017 Jun; 118(6):1432-1441. PubMed ID: 27869314
[TBL] [Abstract][Full Text] [Related]
27. Deletion of core-binding factor β (Cbfβ) in mesenchymal progenitor cells provides new insights into Cbfβ/Runxs complex function in cartilage and bone development.
Wu M; Li C; Zhu G; Wang Y; Jules J; Lu Y; McConnell M; Wang YJ; Shao JZ; Li YP; Chen W
Bone; 2014 Aug; 65():49-59. PubMed ID: 24798493
[TBL] [Abstract][Full Text] [Related]
28. The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells.
Mendoza-Villanueva D; Deng W; Lopez-Camacho C; Shore P
Mol Cancer; 2010 Jun; 9():171. PubMed ID: 20591170
[TBL] [Abstract][Full Text] [Related]
29. Crlz1 activates transcription by mobilizing cytoplasmic CBFbeta into the nucleus.
Park SK; Lim JH; Kang CJ
Biochim Biophys Acta; 2009; 1789(11-12):702-8. PubMed ID: 19735751
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic potential of the RUNX gene family: 'overview'.
Ito Y
Oncogene; 2004 May; 23(24):4198-208. PubMed ID: 15156173
[TBL] [Abstract][Full Text] [Related]
31. A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells.
Oo ZM; Illendula A; Grembecka J; Schmidt C; Zhou Y; Esain V; Kwan W; Frost I; North TE; Rajewski RA; Speck NA; Bushweller JH
Leuk Lymphoma; 2018 Sep; 59(9):2188-2200. PubMed ID: 29249175
[TBL] [Abstract][Full Text] [Related]
32. Functional mutagenesis of AML1/RUNX1 and PEBP2 beta/CBF beta define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain.
Nagata T; Werner MH
J Mol Biol; 2001 Apr; 308(2):191-203. PubMed ID: 11327761
[TBL] [Abstract][Full Text] [Related]
33. The protooncogene product, PEBP2beta/CBFbeta, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures.
Tanaka Y; Watanabe T; Chiba N; Niki M; Kuroiwa Y; Nishihira T; Satomi S; Ito Y; Satake M
Oncogene; 1997 Aug; 15(6):677-83. PubMed ID: 9264408
[TBL] [Abstract][Full Text] [Related]
34. AML1 stimulates G1 to S progression via its transactivation domain.
Bernardin F; Friedman AD
Oncogene; 2002 May; 21(20):3247-52. PubMed ID: 12082641
[TBL] [Abstract][Full Text] [Related]
35. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus.
Veldman RJ; Klappe K; Hinrichs J; Hummel I; van der Schaaf G; Sietsma H; Kok JW
FASEB J; 2002 Jul; 16(9):1111-3. PubMed ID: 12039850
[TBL] [Abstract][Full Text] [Related]
36. Energetic and functional contribution of residues in the core binding factor beta (CBFbeta ) subunit to heterodimerization with CBFalpha.
Tang YY; Shi J; Zhang L; Davis A; Bravo J; Warren AJ; Speck NA; Bushweller JH
J Biol Chem; 2000 Dec; 275(50):39579-88. PubMed ID: 10984496
[TBL] [Abstract][Full Text] [Related]
37. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
[TBL] [Abstract][Full Text] [Related]
38. Differentiation dependent expression and distinct subcellular localization of the protooncogene product, PEBP2beta/CBFbeta, in muscle development.
Chiba N; Watanabe T; Nomura S; Tanaka Y; Minowa M; Niki M; Kanamaru R; Satake M
Oncogene; 1997 May; 14(21):2543-52. PubMed ID: 9191054
[TBL] [Abstract][Full Text] [Related]
39. Ceramide, an apoptotic rheostat, inhibits CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 activation: the role in glutathione S-transferase A2 gene repression.
Park IN; Cho IJ; Kim SG
Drug Metab Dispos; 2004 Sep; 32(9):893-7. PubMed ID: 15319326
[TBL] [Abstract][Full Text] [Related]
40. A mutation in the S-switch region of the Runt domain alters the dynamics of an allosteric network responsible for CBFbeta regulation.
Li Z; Lukasik SM; Liu Y; Grembecka J; Bielnicka I; Bushweller JH; Speck NA
J Mol Biol; 2006 Dec; 364(5):1073-83. PubMed ID: 17059830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
